Purpose During chemotherapy, women with breast cancer not only experience poor quality of life (QOL), they also have little exposure to bright light, which has been shown to be associated with depression, fatigue, and poor sleep in other chronic illnesses. This study examined whether increased light exposure would have a positive effect on QOL. Methods Thirty-nine women with stage I-III breast cancer scheduled to receive C4 cycles of chemotherapy were randomized to a bright white light (BWL, n = 23) or dim red light (DRL, n = 16) treatment group. Data were collected before (baseline) and during cycles 1 and 4 of chemotherapy. Light was administered via a light box (Litebook Ò , Ltd.). QOL was assessed with the Functional Assessment of Cancer Therapy-Breast (FACT-B) and the Functional Outcomes of Sleep Questionnaire (FOSQ). Results Compared with baseline, the DRL group demonstrated significant decline in QOL during the treatment weeks of both cycles (all ps \ 0.02), whereas the BWL group had no significant decline (all ps [ 0.05). Mixed model analyses revealed that there was a group-by-time interaction for FOSQ at the treatment week of cycle 4, and this interaction was mediated by fatigue. Conclusion The data suggest that increased exposure to bright light during chemotherapy may prevent the decline in QOL via preventing the increase in fatigue. 
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Introduction
Oncological treatments have a strong impact on patients' QOL [1, 2] . Decreased QOL has been reported in patients undergoing chemotherapy and in some survivors of breast cancer after chemotherapy [3] [4] [5] . However, chemotherapy itself is likely not the sole cause for decreased QOL, as the stress from a diagnosis of cancer and other related problems are also associated with decreased QOL [6] . For example, fatigue and not chemotherapy was reported as the strongest predictor of QOL [7] . Women are exposed to less bright light both before and during chemotherapy for breast cancer, and this reduced light exposure is associated with more fatigue [8] . Bright light is not only one of the strongest synchronizers of circadian rhythms, but it also has an alerting effect and improves sleep and depression in other populations [9] [10] [11] [12] . Such symptoms as fatigue, poor sleep, and depression usually result in poor QOL.
Our laboratory has shown that bright light therapy keeps fatigue [13] and sleep [14] from deteriorating. This study examined whether increasing bright light exposure might also improve QOL in women with breast cancer undergoing chemotherapy.
Methods
Subjects
Thirty-nine women participated in this study (Fig. 1) . Inclusion criteria were as follows: women 18 years or older, stage I-III breast cancer, scheduled for adjuvant/ neoadjuvant chemotherapy, able to commit to daily morning self-administered light treatment, and fluent in English. Exclusion criteria were as follows: shift workers, pregnant, or with physical or mental impairments. The study was approved by the UCSD Committee on the Protection of Human Subjects and the UCSD Moores Cancer Center.
Procedure
Once written informed consent was obtained, woman were randomized according to a statistically driven randomization table into either the bright white light (BWL; n = 23) or the dim red light (DRL; n = 16) group. A larger proportion was randomized to the BWL group to allow for a larger sample treated with this potentially beneficial, noninvasive treatment. Each participant completed questionnaires on sleep, fatigue, depression, and QOL and wore an actigraphy for 72 h at five time points: before starting chemotherapy (baseline), during the treatment weeks of cycles 1 and 4 (C1TW, C4TW) and the last weeks (recovery week) of cycles 1 and 4 (C1RW, C4RW).
Both BWL and DRL treatments were administered via identical-appearing light boxes (Litebook Ò , Ltd. Medicine Hat, Canada), which emit either 10,000 lux of BWL or less than 50 lux of DRL. Detailed information for the light boxes and their applications is reported elsewhere [15] .
Measures
Quality of life
QOL was assessed with the Functional Assessment of Cancer Therapy-Breast (FACT-B) and the Functional Outcomes of Sleep Questionnaire (FOSQ).
The 36-item FACT-B measures the effect of having breast cancer on functional status. The total score ranges between 0 and 144, with lower scores indicating worse breast cancer-related QOL [16, 17] .
The 30-item FOSQ is designed to measure functional status in situations that produce sleepiness. Its weighted total score ranges between 0 and 20. Lower scores indicate worse sleepiness-related QOL [18] . 
Depressive symptoms
Depressive symptoms were assessed with the 20-item Center for Epidemiologic Studies Depression scale (CES-D). The total score ranges between 0 and 60, with higher scores representing more symptoms of depression [19] .
Fatigue and sleep
Detailed information on fatigue and sleep are reported elsewhere [14, 15] . Briefly, fatigue was measured with the Multidimensional Fatigue Symptom Inventory, and sleep was objectively measured with actigraphy. For the current analysis, total sleep time (TST) and total nap time (NAP-TIME) were analyzed [20] .
Statistical analyses
Summary statistics (means, SEM for continuous variables, and proportions for categorical variables) were computed for all measures. T tests and Fisher's exact tests were used to compare those measures between treatment arms. Mixed effects models were used to assess the effect of light treatment over time. This approach allowed adjustment for potential confounders and also permitted examination of the time trend of outcomes in the two treatment arms. As indicated by residual plots of goodness of fit, total FOSQ scores were cubic-transformed to improve approximation to a Gaussian distribution. A subject-specific intercept term was included in the models to allow for individual variability in outcome. Treatment group, time, and group-by-time interaction were modeled as fixed effects. A significant group-by-time interaction would indicate that changes of measures over time were different in the two treatment arms. For QOL indices that exhibited a group-by-time interaction, a series of mediation analyses [21, 22] would be conducted to examine whether this interaction was mediated by other symptoms.
Results
There were no significant differences between the two groups in terms of the demographic and medical characteristics listed in Table 1 , so no confounders were adjusted in the mixed model analyses.
Quality of life
FACT-B (Fig. 2) There was an overall time effect for the DRL group (p = 0.001) but not for the BWL group (p = 0.2). Total FACT-B scores in the DRL group decreased significantly from baseline to C1TW (p = 0.004) and C4TW (p = 0.0004), while the BWL group had no significant changes from baseline (all ps [ 0.08).
There was no significant group-by-time interaction in total FACT-B scores at any time point (all ps [ 0.2).
FOSQ (Fig. 3)
There was an overall time effect for the DRL group (p \ 0.0001) but not for the BWL group (p = 0.6). Total Mixed model analysis revealed a significant group-bytime interaction at C4TW (p = 0.04) for total FOSQ scores, indicating that decreases from baseline in the DRL group was significantly higher than that in the BWL group at C4TW. There was no significant group-by-time effect at any other time point (all ps [ 0.1).
Since we had previously observed a bright light treatment effect on fatigue [13] and actigraphy-measured TST and NAPTIME [14] , a series of secondary mixed model analyses were conducted to examine whether the light treatment-associated changes of total FOSQ scores were mediated by changes of fatigue or sleep. The results showed that changes of FOSQ from baseline to C4TW were significantly associated with changes in fatigue (p \ 0.0001); when fatigue was added to the mixed model, the group-by-time interaction of FOSQ at C4TW was no longer significant (p = 0.6). These results suggest that the mechanism of light therapy on QOL was primarily through its impact in preventing worse fatigue.
When objectively measured sleep was examined, changes of FOSQ from baseline to C4TW were not significantly associated with changes in TST and NAPTIME, so no further mediation analyses were conducted.
Depressive symptoms (Fig. 4) There was an overall time effect for the DRL group (p = 0.005) but not for the BWL group (p = 0.1). Total CES-D scores in the DRL group increased significantly from baseline to C1TW (p = 0.02) and C4TW (p = 0.0007) while that in the BWL group had no significant changes (all ps [ 0.05).
There was no significant group-by-time interaction in total CES-D scores at any time point during treatment (all ps [ 0.3); thus, depression was not tested as a mediator for QOL.
Discussion
This pilot study showed that women exposed to BWL did not demonstrate a significant decline in QOL, whereas those women exposed to DRL had significantly worse QOL during chemotherapy. Furthermore, exploratory mediation analyses suggested that the effect of light therapy on QOL occurred via the effect of bright light on preventing deterioration of fatigue, rather than the effect of bright light on depressive symptoms or sleep.
The results also show that compared with baseline, women exposed to BWL did not report low breast cancer-related QOL (total FACT-B scores) or more symptoms of depression (total CES-D scores) during chemotherapy, while those exposed to DRL reported lower QOL and more depressive symptoms. However, there was no significant group-by-time interaction; hence, we cannot conclude a definitive impact of light therapy on these two measures.
Various treatment modalities have been studied in women with breast cancer to improve quality of life [23] [24] [25] , but light therapy to date has not been studied or implemented as a means of improving QOL in these women. Findings from this study suggest that bright light may be useful in protecting women from decline in QOL during chemotherapy by protecting women from experiencing more fatigue. The possible mechanism might be that bright light breaks the association between low light exposure and increased fatigue [8, 13] .
Although data from this study did not identify a mediation effect of depression and sleep problems on QOL, given that light therapy has been reported to be effective in the treatment of depression [26, 27] and sleep problems [28, 29] , studies exploring whether light therapy could improve QOL via the effect of improving depression or sleep in cancer patients are warranted.
Limitations of this study include a small sample size, which could have limited study power to detect more significant findings. This small sample size also limited our ability to examine multiple meditational paths; hence, these mediation results should be interpreted cautiously. Follow-up data were not collected in this study, so long-term effect of bright light on QOL could not be determined.
In summary, women with breast cancer undergoing chemotherapy have a decline in overall QOL. Exposure to bright light therapy thwarts this decline by preventing fatigue from deteriorating. Future studies with larger sample sizes should be conducted to further assess the effects of light treatment during and after chemotherapy. In the meantime, oncologists might suggest that patients undergoing chemotherapy to increase their exposure to bright light either by going outside in the morning or by using a light box to improve QOL, as this treatment is safe, inexpensive, easy to use, and may be less time-consuming and more convenient than other interventions, such as attending social support groups or exercising.
